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Statement of Translational Relevance:  The field of nanomedicine has highly debated the 
presence and extent of the enhanced permeability and retention (EPR) effect in human tumors, a 
key mechanistic hallmark for nanomedicine to achieve effective drug delivery and subsequent 
therapeutic benefits.  In this translational study, 64Cu-labeled HER2-targeted liposomal 
doxorubicin was quantified by positron emission tomography (PET) and found to accumulate in 
human tumors.  Based on 64Cu-PET quantification, the range of tumor drug concentrations is 
predicted to result in variable anti-tumor activity.  High tumor deposition was stratified based on 
a cutoff that is consistent with preclinical studies, and was associated with more favorable 
treatment outcome.  This suggests that a nanoparticle imaging approach may be applicable as a 
biomarker strategy for personalizing nanomedicines. 
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Abstract:  
Purpose:  Therapeutic nanoparticles are designed to deliver their drug payloads through 
enhanced permeability and retention (EPR) in solid tumors.  The extent of EPR and its variability 
in human tumors is highly debated and has been proposed as an explanation for variable 
responses to therapeutic nanoparticles in clinical studies.   
Experimental Design:  We assessed the EPR effect in patients using a 64Cu-labeled 
nanoparticle, 64Cu-MM-302 (64Cu-labeled HER2-targeted PEGylated liposomal doxorubicin), 
and imaging by Positron Emission Tomography/Computed Tomography (PET/CT).  Nineteen 
patients with HER2-positive metastatic breast cancer underwent 2-3 PET/CT scans post-
administration of 64Cu-MM-302 as part of a clinical trial of MM-302 plus trastuzumab with and 
without cyclophosphamide (NCT01304797). 
Results:  Significant background uptake of 64Cu-MM-302 was observed in liver and spleen.  
Tumor accumulation of 64Cu-MM-302 at 24-48 h varied 35-fold (0.52 to 18.5 %ID/kg) including 
deposition in bone and brain lesions, and was independent of systemic plasma exposure.  
Computational analysis quantified rates of deposition and washout, indicating peak liposome 
deposition at 24-48 h.  Patients were classified based on 64Cu-MM-302 lesion deposition using a 
cut-point that is comparable to a response threshold in preclinical studies.  In a retrospective 
exploratory analysis of patient outcomes relating to drug levels in tumor lesions, high 64Cu-MM-
302 deposition was associated with more favorable treatment outcomes (hazard ratio = 0.42). 
Conclusions:  These findings provide important evidence and quantification of the EPR effect in 
human metastatic tumors, and support imaging nanoparticle deposition in tumors as a potential 
means to identify patients well-suited for treatment with therapeutic nanoparticles. 
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Introduction 
Nanoparticle drug delivery systems provide a means to alter the biodistribution and 
pharmacokinetics of small molecule drugs. Such systems are of particular importance in 
oncology, where there is a need to improve the toxicity profiles and therapeutic windows for 
small molecule chemotherapies.  Therapeutic nanoparticles can enable long-circulating 
pharmacokinetics and tunable sustained release and improved deposition in solid tumors through 
leaky vasculature.  This phenomenon is referred to as the enhanced permeability and retention 
(EPR) effect, and is well characterized in animal models (1–3).  The extent to which the EPR 
effect is present in human tumor lesions remains controversial but has been proposed as an 
explanation for variable responses to nanotherapeutics, and has important implications for the 
development and design of future nanomedicines (3,4). 
Liposomes are a class of nanomedicines that have been proven to be clinically useful 
drug delivery vehicles, with several approved agents for cancer treatment (Doxil®/Caelyx®, 
Myocet®, DaunoXome®, Marqibo®, ONIVYDE®).  The large size of liposomes, typically about 
100 nm in diameter, prevents extravasation from normal vasculature and results in deposition 
and retention in areas of functionally porous vasculature, such as the liver and spleen, or leaky 
vasculature in some tumor lesions and areas of inflammation (5–7).  Deposition of liposomes via 
the EPR effect is a non-specific phenomenon governed primarily by their size and surface 
characteristics (8,9).  
MM-302 (HER2-targeted PEGylated liposomal doxorubicin) is a nanoparticle in clinical 
development for patients with HER2-positive metastatic breast cancer (NCT01304797, 
NCT02213744).  Targeting of liposomes to tumor antigens, such as HER2, serves as means to 
alter the microdistribution of liposomes within tumor lesions and to direct deposited liposomes 
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into tumors cells rather than macrophages (10).  MM-302 was specifically designed to maximize 
doxorubicin uptake into tumor cells while minimizing uptake into non-target cells and tissues 
(11) and to enable combination with trastuzumab (12).  While many have reported that antigen-
targeted nanoparticles can lead to increased tumor uptake, the extent to which targeted 
nanoparticles can enhance tumor uptake is determined by many factors such as choice of 
targeting ligand and particle size (13–15).  For some nanoparticles, tumor accumulation is 
independent of targeting ligand and, therefore, may be dictated primarily by the EPR effect.  
Previous work in preclinical models has demonstrated that the HER2-targeting did not alter 
overall deposition of MM-302 into tumors (Supplementary Fig. S1), but only altered the cellular 
fate within the tumors (10).  
Effective drug delivery is a necessary step for anti-tumor activity, and poor penetration of 
anticancer drugs is believed to limit the effectiveness of chemotherapy in solid tumors (16–18).  
As molecular size of a therapeutic agent increases, effective delivery becomes increasingly 
important (19).  In preclinical models, effective tumor deposition of nanoparticles has also been 
shown to be a potentially rate-limiting step for effective drug delivery to tumor cells and the 
resulting anti-tumor activity (20–23). 
The goal of this study was to understand the biodistribution and evaluate the potential 
role of the EPR effect on a nanotherapeutic in patients with metastatic breast cancer in order to 
determine whether tumor lesion delivery could ultimately be used to predict therapeutic efficacy.  
We transformed a HER2-targeted liposomal doxorubicin (MM-302) into a tracer for positron 
emission tomography (PET) through labeling with 64Cu to enable quantitative characterization of 
tumor delivery kinetics.  64Cu is a positron-emitting radionuclide with a 12.7 h half-life, well 
matched to the pharmacokinetics of MM-302.  We demonstrated the clinical feasibility and 
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safety of 64Cu-liposome PET in patients.  64Cu retention within liposomes was shown to be stable 
in patients within the image acquisition time frame.  Computational modeling enabled detailed 
elucidation of the EPR kinetics, establishing both the deposition and washout components of 
tumor delivery.  Variability of the EPR effect was established across lesions within a patient and 
across patients, as well as in non-target tissues including the liver, spleen, and bone marrow.  
Despite heterogeneity at the individual lesion level, we described a method of patient 
classification based on minimum lesion deposition and demonstrated association of tumor 
deposition with response to treatment. 
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Materials and Methods 
Clinical Study Overview 
Patients imaged with 64Cu-MM-302 PET were part of a multi-site Phase 1 MM-302 study 
(NCT01304797).  A companion imaging protocol was included after the dose escalation phase in 
which all patients who consented underwent 64Cu-MM-302 PET.  The primary objectives of the 
64Cu-MM-302 PET study were to determine the radiation dosimetry and biodistribution of 64Cu-
MM-302.  The study was conducted following International Conference on Harmonization 
guidelines in accordance with Good Clinical Practice and the ethical principles based on the 
Declaration of Helsinki.  The study was reviewed and approved by the local Institutional Review 
Board at each center prior to the start of the study and each subject gave written informed 
consent. 
 
Patients 
Patients enrolled in this study were ≥ 18 years of age and had advanced HER2-positive 
(i.e., HER2 3+ by IHC, or HER2 2+ by IHC and FISH or CISH-positive disease) breast cancer, 
measureable disease by RECIST v1.1, an Eastern Cooperative Oncology Group performance 
status of 0–1, adequate bone marrow reserves (absolute neutrophil count (ANC) ≥ 1,500/µL , 
platelet count ≥ 100,000/µL, hemoglobin ≥ 9 g/dL), adequate hepatic function (serum total 
bilirubin within normal limits, aspartate aminotransferase (AST), alanine aminotransferase 
(ALT) up to 2x Upper Limit of Normal (ULN)), adequate renal function (serum creatinine ≤ 1.5 
x ULN), and adequate cardiac function (left ventricular ejection fraction of ≥ 50% by 
echocardiography or radionuclide ventriculography).  The main exclusion criteria were total 
cumulative doxorubicin >300 mg/m2, active infection or unexplained fever, symptomatic brain 
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metastases, congestive heart failure, coronary artery disease, history of myocardial infarction, 
hypertension, angina pectoris, valvular heart disease, severe and/or uncontrolled ventricular 
arrhythmia, prolonged QTc interval, history of allogeneic transplant, and infection of HIV, 
hepatitis B or C.  
 
MM-302, trastuzumab, and cyclophosphamide dose 
Patients imaged with 64Cu-MM-302 PET were in Arms 3 and 4 of the Phase 1 study 
(NCT01304797) and received the following treatment:  trastuzumab at 6 mg/kg (with an 8 mg/kg 
loading dose on cycle 1) administered as a 90-minute IV infusion, MM-302 at 30 mg/m2 
administered as a 60-minute IV infusion, as well as a tracer dose of 64Cu-MM-302 as described 
below.  The first 3 patients of Arm 3 received trastuzumab starting on cycle 2 in order to enable 
initial safety assessment of 64Cu-MM-302.  Patients in Arm 4 also received cyclophosphamide at 
450 mg/m2 5 days prior to 64Cu-MM-302 based on a preclinical study showing that tumor 
priming with cyclophosphamide enhanced tumor delivery of MM-302 in xenografts (24).  All 
patients received prophylactic premedication with diphenhydramine or equivalent prior to dosing 
of MM-302. 
 
64Cu-MM-302 dose 
64Cu-MM-302 was prepared by a commercial radiopharmacy using 64CuCl2 obtained 
from Washington University (St. Louis, MO USA), a chelating/loading agent (Diacetyl 4,4′-
bis(3-(N,N-diethylamino)propyl)thiosemicarbazone, or 4-DEAP-ATSC), and MM-302. 2.5 mL 
of 0.06 mg/mL 4-DEAP-ATSC was added to 64CuCl2 and incubated for 1 min at room 
temperature.  The chelated 64Cu mixture was passed through a 0.2 µm filter into a vial containing 
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5 mL of 2 mg/mL MM-302.  The mixture was heated to 65°C for 10 min and then cooled to 
room temperature.  The efficiency of loading was measured by size exclusion chromatography as 
previously described (25).   
Quality control testing for 64Cu-MM-302 consisted of total activity (400 MBq ± 10%), 
radiochemical purity (64Cu loading efficiency ≥ 85%), appearance (red opalescent solution), 
endotoxin (≤ 35 EU/mL), and sterility.  The effect of 64Cu labeling on MM-302 was found to 
have negligible effects on key MM-302 characteristics (HER2-binding, doxorubicin content, 
phospholipid concentration) and maintain an acceptable pH for administration.  Preclinical 
characterization and stability of 64Cu-MM-302 was reported elsewhere (25). 
For all patient doses, radiochemical purity was observed in the range of 95-99%.  Within 
3 hours after administration of 30 mg/m2 MM-302 (doxorubicin equivalent), approximately 400 
MBq of 64Cu-MM-302 (approx. 3-5 mg/m2 doxorubicin) in 3-7 mL (depending on the 64Cu-
labeling specific activity at the time of administration) was administered as an IV infusion over 
10 min using an infusion pump, followed by a saline flush. 
 
PET image acquisition and quantification 
Each patient underwent PET/CT 0-3 h after administration of 64Cu-MM-302 on Day 1 
and additional scan(s) on Day 2 and/or Day 3 depending on scan group assignment upon 
enrollment.  Five of the nineteen patients consented to all three scan times.  Image acquisition 
times on Days 1, 2 and 3 were 3-5, 7-9 and 12-15 min per bed position, respectively.  
Approximately 6 bed positions were obtained for each patient, spanning from mid-brain to mid-
thigh axially. 
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Quantification of images was performed using MIM software (MIM Software Inc.; 
Cleveland, OH.; Version 6.2 or higher).  Rather than maximum standardized uptake value 
(SUVmax), tracer concentration was reported as the percent injected dose per kg of tissue 
(%ID/kg) within a region of interest (ROI), derived from SUVmedian normalized to body weight 
(BW).  %ID/kg is related to SUV in the following manner:  %ID/kg tissue = SUV/BW*100%.  
This measure provides a quantitative measure of drug concentration in the ROI.  It is 
hypothesized that drug activity will be closely related to absolute drug concentration, and for this 
reason, SUVmax, which is conventionally used to correlate with tumor metabolic activity (in the 
context of 18F-fludeoxyglucose (FDG)) is not appropriate.  The median tissue uptake was 
determined by creating a 3D ROI in metastatic lesions and in normal tissues (heart, lung, liver, 
spleen, kidneys).  Tumor lesion ROIs were selected by an independent radiologist board-certified 
in nuclear medicine.  The median radioactivity for all tumor lesions and tissues were exported 
from the MIM software into an electronic case report form (eCRF) for further analysis.  As an 
exploratory analysis, bone marrow uptake was quantified using an 8 mm spherical ROI in the 
lumbar vertebrae (average of L1-L5).  Vertebrae with bone metastases or sclerotic lesions based 
on CT were excluded from normal bone marrow analyses. 
 
Safety Monitoring 
Safety of the underlying chemotherapy regimen is reported elsewhere (26,27).  Briefly, 
vital signs were monitored at multiple time points, both before and after the MM-302 and 64Cu-
MM-302 administrations.  Hematology, liver, and kidney functions were assessed throughout the 
study.  Continual follow-up assessment for adverse events at each study visit was in place to 
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monitor for any possible sequelae of the radiopharmaceutical imaging study.  Safety of 64Cu-
MM-302 as a PET tracer was established through radiation dosimetry as described below. 
 
Radiation dosimetry 
Data were presented as PET image files to an independent medical physicist with 
expertise in radiopharmaceutical dosimetry.  Counts in tissues were extracted from the images 
using the MIPAV software (28).  Activity in each visualized organ and the total body were 
expressed as fractions of injected activity, normalizing the activity in the whole body at the 
earliest time point to be 100% of the administered activity.  Resultant values of percent of 
injected activity per organ were fit using the SAAM II software (29).  Time integrals of activity 
(30) were entered into the OLINDA/EXM software (31), using the adult male model.  The 
number of disintegrations in the ‘remainder of body’ was assumed to be that in total body within 
the field of view minus the values in other organs of uptake. 
 
Tracer kinetic modeling 
The tracer kinetic model used follows a general form previously presented for describing 
liposome transport into and out of tumors (20,32).  The PK of 64Cu-MM-302 was represented 
with a single blood compartment with volume Vc and clearance characterized by elimination rate 
constant kel. The tumor (volume = Vt, assuming tissue density ρ = 1 kg/L) was described in a 
semi-physiological manner with a vascular portion and tissue portion consisting of cellular and 
interstitial space.  The fractional volume of the tumor occupied by vasculature was described by 
a vascular volume fraction (VVF).  Blood flow rate into and out of the tumor (Q) was assumed 
constant at 0.0282 L/kg/min (33).  Washout of particles from the tumor, either back into the 
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blood or via lymphatic drainage, is lumped into a single process for simplicity.  Deposition and 
washout of 64Cu-MM-302 into and out of the tumor tissue space was assumed to follow first-
order kinetics and were characterized by rate constants k1 and k-1, respectively. 
Equations are listed below: 
 
where Cb, Ctv, Ctt, Ct,total are the concentrations of 64Cu-MM-302 in the blood, tumor vasculature, 
tumor tissue, and total tumor, respectively.  The following parameters were estimated directly 
from the kinetic data: kel, VVF, k1, k-1 using median values extracted from ROI analysis from the 
images and associated tumor volume measurements.  Additional information on the model 
parameters are provided in Supplementary Table S1.  The model was implemented in MATLAB 
(The Mathworks, Natick, MA). 
 
Statistical Analysis 
Treatment outcome was not assessed on the companion imaging protocol, but was 
documented under the parent protocol per RECIST v1.1 criteria.  Image-based ROI analysis data 
was captured using an eCRF developed in compliant with 21 CFR Part 11, with the exception of 
the bone marrow uptake data that were obtained for additional exploratory analysis.  Uptake data 
were then exported for further computational analyses.  Statistical and PK analyses were 
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performed using MATLAB (The Mathworks, Natick MA) or GraphPad Prism version 6.0 
(GraphPad Software, San Diego, CA).  Only nonparametric statistical tests were utilized, 
including Mann-Whitney, Kruskal-Wallis, or Spearman Correlation, wherever applicable.  Data 
are shown as median [interquartile range] unless otherwise indicated. 
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Results  
It is well established that there is a dose-activity relationship for liposomal anti-cancer 
agents in preclinical tumor models (34).  We therefore sought to identify the minimum tumor 
delivery of MM-302 required for anti-tumor activity in preclinical models (details described in 
Supplementary Materials).  As expected, increased tumor delivery was observed with increasing 
dose (Supplementary Fig. S2A; range: 1-13 µg doxorubicin per gram of tumor tissue, or µg 
DOX/g).  The 3 mg/kg dose level, roughly corresponds to the dose level at which MM-302 can 
effectively inhibit tumor growth (Supplementary Fig. S2B), resulted in a minimum tumor 
concentration of 2.3 µg DOX/g.  Based on these findings, we sought to determine the 
concentrations of liposomal drug achieved in tumor lesions in patients, and hypothesized that a 
minimum effective dose would be necessary for effective treatment with liposomal therapies 
such as MM-302. 
 
PET/CT of 64Cu-MM-302 in patients 
Between July 2013 and July 2014, 25 patients were dosed with MM-302 as part of a 
Phase 1 study (NCT01304797); 19 of the patients underwent 64Cu-MM-302 PET.  Patient 
demographics are shown in Supplementary Table S2.  All 19 patients were imaged on Day 1 
between 0.2-2h (median 0.7 h) post-administration of 64Cu-MM-302; 16 and 8 patients also 
underwent scans on Day 2 (median of 21.2 h) and Day 3 (median of 44.6 h), respectively.  A 
total of 5 patients had 3 PET scans on Days 1, 2, and 3 post-administration.  The median age of 
imaged patients was 54 (range: 41-71) and the median body weight was 71.7 kg (range: 50.5-
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97.3 kg).  Patients were enrolled into two different arms where arms 3 and 4 include treatment 
with trastuzumab + MM-302 and cyclophosphamide + trastuzumab + MM-302, respectively.  
The mean activity of 64Cu-MM-302 administered was 389 MBq (range: 337-432 MBq).  
The administration of 64Cu-MM-302 was well tolerated by all subjects.  Any study drug related 
adverse events recorded could not be uniquely attributed to 64Cu-MM-302 because 64Cu-MM-
302 is administered within a few hours of MM-302, and the exposures to the two molecules 
overlap during the period of treatment emergent adverse event reporting. 
 
Pharmacokinetics and Biodistribution of 64Cu-MM-302 
Whole-body distribution of 64Cu-MM-302 is shown for two patients on Days 1-3 post-
administration in Fig. 1.  Immediately following administration, 64Cu-MM-302 is almost 
exclusively localized in the blood pool, as expected for a PEGylated liposome.  On Days 2-3 (19-
47 h), deposition of 64Cu-MM-302 was seen in the liver and spleen, but there was relatively slow 
clearance from the blood.  Images were consistent with hepatic clearance of MM-302 and no 
significant uptake of the tracer was seen in the kidneys or bladder of any patients.  
Decay-corrected time-activity plots for 64Cu-MM-302 in selected normal tissues are 
shown in Fig. 2 for all patients.  Because of the relatively long circulation time of 64Cu-MM-302, 
the presence of large blood vessels in any ROI has the potential to skew the average values 
within an ROI.  For this reason, median activity within each ROI was used to provide a more 
robust measure of tissue uptake.  There was very little uptake in normal muscle and normal lung 
tissue (< 6 %ID/kg).  Median normal liver uptake was approximately 6.5 [5.2-7.3] %ID/kg post-
administration and increased with time to 15.7 [12.4-21.8] %ID/kg on Day 3 (decay-corrected).  
Uptake into normal spleen appeared to be the most variable with 10.5 [8.6-13.3] %ID/kg post-
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administration, with a mild increase to 17.0 [13.5-18.3] and 13.2 [7.8-19.6] %ID/kg on Days 2 
and 3, respectively.  64Cu-MM-302 uptake was also observed in the bone marrow, peaking 
between Days 2-3 at 4.2 [3.6-4.7] and 3.6 [2.0-4.0] %ID/kg, with similar uptake kinetics as 
normal spleen; this is consistent with the expected uptake of nanoparticles by the 
reticuloendothelial system (RES) (35).  Although the level of uptake in bone marrow seems to be 
on par with that of lung tissue, the kinetics of bone marrow uptake resemble that seen in the 
liver/spleen instead of the constant decrease observed for muscle and lung (i.e., blood clearance). 
The behavior of 64Cu-MM-302 in the blood pool was assessed from PET/CT images 
using an ROI in the aorta and is shown in Fig. 2F and G.  The clearance of 64Cu-MM-302 was 
highly reproducible and consistent with mono-exponential clearance kinetics previously reported 
for MM-302 based on doxorubicin content (26,27).  Mono-exponential clearance kinetics made it 
possible to determine estimates of the pharmacokinetic parameters from the 2-3 images obtained 
per patient.  Estimation of pharmacokinetic parameters (compartment model) from the imaging 
data (mean t1/2 = 33 h) compared well with the 39 h (95% CI = 29-53 h; n=10) half-life reported 
for MM-302 at the 30 mg/m2 dose level (26).  One patient had significantly faster blood 
clearance (t1/2 = 9.53 h) with significant sequestration of 64Cu-MM-302 at 0.5 h in the liver and 
spleen (Supplementary Fig. S3).  This patient was in Arm 4 (with cyclophosphamide treatment) 
but rapid clearance does not seem to be attributed to cyclophosphamide, as the blood t1/2 was not 
significantly different in Arm 3 without cyclophosphamide (median t1/2 = 36.5 [23.6-44.3] h) 
compared to Arm 4 (median t1/2 = 35.4 [25.2-40.9] h; p = 0.97).  Most normal tissue uptake 
between the two groups were also comparable, with the exception of muscle on Day 1 (Arm 3 = 
1.9[0.6-1.3] %ID/kg vs. Arm 4 = 0.6[0.3-0.8] h; p = 0.027) and bone marrow on Day 2 (Arm 3 = 
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4.3[4.1-5.4] %ID/kg vs. Arm 4 = 3.9[2.9-4.4] h; p = 0.042) where Arm 3 patients have higher 
uptake. 
The stability of 64Cu labeling of MM-302 was assessed in 3 patients.  Free 64Cu was not 
detectable above background any time point (Supplementary Fig. S4), indicating highly stable 
labeling of MM-302 with 64Cu.  In addition, almost all the 64Cu activity remained in the serum 
component, with <4% 64Cu detected in blood cells.  These results were consistent with 
preclinical development of the 64Cu-MM-302 labeling method (25). 
 
Radiation Dosimetry 
Internal radiation dosimetry was evaluated in a subset of patients (n=11).  The target 
radioactivity was 400 MBq, and the median radioactivity administered to the 11 patients for 
radiation dosimetry analysis was 389 (range: 337-432) MBq.  The mean estimated radiation 
absorbed dose for each organ, effective dose and total body dose are shown in Supplementary 
Table S3.  The highest absorbed radiation dose was in the heart wall, followed by the spleen, and 
liver receiving 0.25 [0.20-0.31], 0.12 [0.09-0.21], and 0.09 [0.09-0.12] mGy/MBq, respectively.  
The median effective dose was 0.028 mSv/MBq. 
 
Tumor lesions uptake of 64Cu-MM-302 
Tumor lesions could be visualized on Days 2 and 3 of 64Cu-MM-302 PET scans (Fig. 3).  
Similar to normal tissue uptake, there was no significant difference in lesion uptake for patients 
treated vs. not treated with cyclophosphamide (Arm 3 vs. 4, p ≥ 0.67 for all 3 scans) (Fig. 4A).  
Based on these findings, subsequent analyses were performed by combining data from the two 
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treatment arms.  Increasing activity in tumor lesions were noted from the initial scan on Day 1 to 
Days 2-3 scans at varying degrees (Fig. 4B) while the activity in the blood decreased over this 
time frame (Fig. 2F).  In the initial scan, median 64Cu-MM-302 signal in lesions was 2.3 %ID/kg 
(range: 0.24-7.1 %ID/kg, n=68 lesions), reflecting predominantly tumor blood pool.  
Comparison with blood measurements yield a ratio of 0.13, which is consistent with the expected 
tumor vascular volume fraction determined by other methods (36–38).  The median tumor-to-
blood ratios were 0.080 [0.045-0.120], 0.208 [0.082-0.188], and 0.468 [0.111-0.451] on Days 1, 
2, and 3, respectively.  There were a few lesions that showed either no change or a decrease in 
signal over time, but did not decrease as rapidly as the blood pool signal, still suggesting a small 
degree of 64Cu-MM-302 deposition.  Median 64Cu-MM-302 deposition on Days 2 and 3 were 3.7 
[2.8-7.5] and 4.0 [2.3-10.6] %ID/kg indicating no significant differences in lesion uptake 
between Day 2 and Day 3. 
Based on the known 64Cu-to-doxorubicin ratio, it is estimated that the tumor deposition of 
MM-302 on Days 2-3 range from 0.22 to 11 µg DOX/g.  90% of the patient lesions had 
deposition that are consistent with the range of MM-302 tumor uptake in preclinical xenograft 
models (Supplementary Fig. S2A, range:  1-13 µg DOX/g).  64Cu-MM-302 uptake was 
heterogeneous within each patient among multiple lesions (Fig. 4C).  The extent to which 64Cu-
MM-302 accumulates in individual lesions is therefore unique to the lesion characteristics rather 
than the pharmacokinetics of 64Cu-MM-302, as lesion uptake on Days 2 or 3 was not correlated 
with exposure (p > 0.08, Pearson Correlation with blood AUC0→∞; Fig. 4D).  There was also no 
significant correlation between lesion signal and lesion volume (p > 0.27) for Scan 2 or 3 (Fig. 
4E). 
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Uptake was observed in lesions of various anatomical locations, including the lung, brain, 
lymph nodes and bone, as shown in Fig. 3 with deposition quantification presented in Fig. 4F.  
Hepatic lesions primarily appeared as hypo-active regions, because of the high background 
activity of the liver, but showed evidence of signal enhancement over time.  There were also 
several instances where hepatic lesions had uptake similar to that of normal liver tissue, requiring 
reference to contrast-enhanced diagnostic CT to guide ROI selection (Supplementary Fig. S5).  
In all 3 scan time points, hepatic lesions were consistently higher than other anatomical locations 
(Fig. 4F; p < 0.0001 on Days 2 and 3; only anatomical locations with more than 3 data points 
were included in statistical analyses). 
 
Kinetics of 64Cu-MM-302 tumor deposition 
In patients who consented to undergo 3 scans, a detailed kinetic analysis of 64Cu-MM-
302 in tumor lesions was possible.  Fig. 5 shows the 64Cu-MM-302 lesion deposition kinetic 
profiles of a patient, who had 4 tumor lesions that were selected for analysis by the independent 
reviewer.  Quantification of 64Cu-MM-302 uptake for the individual lesions is shown in Fig. 5A. 
A chest wall lesion showed comparatively high uptake on Day 3 while the two hepatic lesions 
and one neck lesion had comparatively lower uptake.  Images corresponding to comparatively 
high (ROI 3) versus low (ROI 4) uptake lesions are shown in Fig. 5B. 
Three imaging data points and a basic set of assumptions regarding 64Cu-MM-302 
transport (see Materials and Methods) enabled elucidation of the full kinetics of 64Cu-MM-302 
deposition into and out of the tumor lesions including determination of the contribution of blood 
versus tissue-deposited 64Cu-MM-302.  A schematic of the tracer kinetic model used is shown in 
Fig. 5C.  The model assumes first-order clearance of 64Cu-MM-302 from the central blood pool 
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and a fixed rate of convective transport (blood flow) from the central compartment into the 
vascular compartment of the tumor.  The tumor is characterized by a vascular volume fraction 
and 64Cu-MM-302 transport from the vascular compartment into the tissue, through a 
combination of convective and diffusive transport, is characterized by a first-order rate constant.  
Washout of 64Cu-MM-302 is also assumed to follow first-order kinetics.  Cellular uptake and 
processing of 64Cu-MM-302 is also assumed to be minimal over the 3-day time scale of imaging.  
Shown in Fig. 5D, the kinetic model was fit to the blood and tumor data, demonstrating that this 
model framework was able to quantify the inter-lesion heterogeneity of uptake through variations 
in rates of deposition, washout, and vascular volume fraction (Supplementary Fig. S6).  The 
model results indicate peak deposition of MM-302 in human tumors occurs on approximately 
Days 2-3 and supports the selected imaging times used.  The fraction of tumor 64Cu-MM-302 
signal on Days 2-3 arising from the vascular versus deposited 64Cu-MM-302 was minimal 
compared to the tumor tissue signal, suggesting that most 64Cu tumor signal after Day 1 is 
attributed to deposition of 64Cu-MM-302 in the tumor tissue. 
 
Patient classification and association with treatment outcome. 
Inadequate drug delivery to a single tumor lesion within a patient may be sufficient to 
result in progressive disease when patients are evaluated based on RECIST v1.1.  For this reason, 
we classified patients into two groups based on their lowest uptake lesion.  At approximately 2 
%ID/kg, a plateau was observed based upon the distribution of lowest uptake lesion deposition 
of each patient (Fig. 6A).  Tracer deposition of 2 %ID/kg corresponds to approximately 1.2 µg 
DOX/g, which is comparable to the preclinical effective threshold established previously (2.3 µg 
DOX/g; Supplementary Fig. S2).   
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Although not a formal objective of the study, a preliminary retrospective analysis was 
attempted to correlate 64Cu-MM-302 lesion uptake and patient response to treatment.  The best 
overall responses per RECIST v1.1 for the two groups classified based on imaging data are 
shown in Fig. 6B to D.  75% of subjects experienced a partial response (PR) and/or stable 
disease (SD) in the high deposition group, while 43% of patients experienced SD with no PR in 
the low deposition group.  The patients in groups with the low and high 64Cu-liposome 
deposition lesions had median progression free survival (PFS) of 1.7 and 2.0 months, 
respectively, with a hazard ratio of 0.42 (logrank method).  ROC analysis of the minimum lesion 
uptake against PFS yielded a deposition threshold of 2.4 %ID/kg, which resulted in the same 
patient stratification.  The limited number of imaged patients on each treatment arm with 
analyzable RECIST data (n= 9 and 10 for Arms 3 and 4, respectively) precluded a meaningful 
statistical comparison. 
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Discussion  
The extent of therapeutic nanoparticle deposition in solid tumors is a vital component of 
establishing local drug concentrations and the overall therapeutic window.  Understanding the 
extent and variability of the EPR effect in patient tumors is at the core of understanding whether 
local drug levels are limiting in patient responses to therapeutic nanoparticles (3).  While 
preclinical examples exist, this simple pharmacological concept has been difficult to translate 
into the clinical setting (39). 
In this study, we utilized preclinical models to identify a minimum critical concentration 
threshold of MM-302 tumor delivery required to control tumor growth and translated this 
concept into a clinical study.  We hypothesized that tumor lesion delivery of therapeutic 
nanoparticles such as MM-302 are highly variable, and locally achievable drug concentrations 
span critical thresholds that determine sensitivity versus lack of response.  In order to test this 
hypothesis, we transformed MM-302 into a PET tracer through 64Cu-labeling and incorporated 
imaging with 64Cu-MM-302 PET/CT into a clinical trial of MM-302 plus trastuzumab with or 
without cyclophosphamide.  Patient tumor concentrations of MM-302, as determined with 64Cu-
MM-302, were remarkably consistent with those determined from preclinical data, and span a 
range of concentrations that potentially impact therapeutic responses.  Our results have important 
implications for clinical development of therapeutic nanoparticles. 
To date, patients with cancer have been imaged in several clinical studies with 111In-
liposomes or 99mTc-liposomes via planar scintigraphy or single-photon emission computed 
tomography (SPECT) to assess tumor uptake of the liposomes (40–43).  However, these clinical 
studies were limited to visualization or semi-quantitative analysis of liposome behavior because 
of the limitations of the imaging methods and/or the short half-life of the radionuclide tracer.  
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Relative to SPECT, PET has the advantage of increased sensitivity and spatial resolution while 
allowing for straightforward data quantification and whole-body 3D imaging.  
The kinetic nature of our studies with 64Cu-MM-302, coupled with the accuracy afforded 
by PET/CT, clearly establish that the EPR effect is present in human metastatic tumors.  The 
accumulation of 64Cu-MM-302 in tumor lesions over time was not observed in normal tissues 
such as muscle, and is consistent with the EPR effect of nanoparticles as reported in the literature 
(44,45).  The data indicate the variable nature of this process, not only in terms of deposition 
rates but washout rates as well.  Rates of deposition and washout determined from human tumors 
compared well with rates estimated from mouse xenograft models (20).  Further, kinetic 
modeling indicated that at later times the 64Cu signal was predominantly the result of tissue-
deposited liposomes.  By contrast, early imaging times, as used in 99mTc-liposomes studies, are 
largely a measurement of tumor lesion vascular volume fraction (41–43). 
This study also highlights the interplay between normal liver and hepatic tumor lesions 
for therapeutic nanoparticles.  As expected, the liver was a site of high background signal 
because of its role in metabolizing and clearing liposomes.  By contrast, little to no signal was 
observed in the kidney or bladder, supporting the stability of the 64Cu-MM-302 tracer, as well as 
the liver being the primary route of clearance.  The liver is also a common site of metastatic 
disease in breast and other cancers.  Hepatic lesions were able to be visualized in most cases as 
they tend to appear as hypo-active regions relative to the high normal tissue uptake background.  
In some cases, where hepatic lesion uptake was similar to normal liver tissue, diagnostic CT was 
required to help delineate the liver-lesion boundary.  The spatial resolution of PET and partial 
volume effects make accurate quantification of these lesions difficult.  This may be particularly 
true for lesions with an actively growing rim and/or necrotic core.  Similarly, lesions with 
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significant fibrosis or scar tissue may also be difficult to resolve from actively growing lesions 
by CT.  For these reasons, comparison of 64Cu-MM-302 PET with 18F-FDG PET would be an 
interesting future direction for identifying metabolically active lesions to further the 
understanding of liposome tumor deposition. 
The data presented herein provide evidence supporting a mechanism by which 64Cu-MM-
302 liposomes deposit and accumulate in human tumors.  An interesting and serendipitous 
finding of this study was the accumulation of 64Cu-MM-302 in brain lesions.  The delivery of 
large molecules to brain lesions has been previously shown by imaging with liposomes (41) and 
64Cu-/89Zr-labeled trastuzumab (46,47).  Similarly, Siegal et al. had reported a 14-fold increase 
in liposomal doxorubicin delivery to brain tumor in a mouse model compared to adjacent normal 
brain tissue (48).  This almost certainly reflects disruption of the blood-tumor-barrier in 
metastatic lesions, rather than large liposomes traversing the blood-brain-barrier directly.  
Greater disruption would be predicted to lead to increased delivery and might determine the 
extent of response to therapy (49,50). 
Variable 64Cu-MM-302 uptake occurred both across lesions within a patient and across 
patients.  In general, in patients with multiple lesions, not all of the lesions had the same level of 
uptake.  This suggests that patient classification based on nanoparticle delivery is potentially 
complex, and cannot be solely determined by systemic exposure.  However, patient lesion data 
can be classified into two groups: (i) variable uptake including low-uptake lesions, and (ii) 
variable uptake with only high-uptake lesions, based on the rationale that poor delivery to a 
single lesion could be sufficient to presage disease progression.  Classification based on imaging 
data selected about one-third of patients as “low uptake” and enabled a subsequent exploratory 
analysis of patient outcomes.  Although our retrospective analysis illustrates that patient level 
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classification based on lesion delivery is possible and was consistent with our delivery-based 
hypothesis, these results are limited by the small sample size of this Phase 1 study among other 
factors, including the inherent chemosensitivity.  For instance, patient classification was 
performed based on the imaging data only; however, some patients received cyclophosphamide 
and others did not.  Nonetheless, we did not find a systematic difference in lesion uptake 
between lesions that were treated with cyclophosphamide versus those that were not, suggesting 
this was not a primary factor in dictating outcome. 
The significance of this work also extends to an improved understanding of safety.  EPR 
effect also occurs in bone marrow and explains well-known hematological toxicities of 
therapeutic nanoparticles such as liposomal doxorubicin.  Interestingly, less variability in uptake 
was observed in bone marrow than in tumor lesions, in general.  This implies that the primary 
opportunity for patient selection lies in identifying patients based on uptake in tumor lesions 
rather than safety. 
Together, these data suggest that it may be possible to use pretreatment imaging of 
nanoparticle deposition in tumors as a potential means to identify patients most likely to benefit 
from treatment with therapeutic nanoparticles.  Future directions include development of 
potential diagnostic imaging agents specifically designed to assess tumor delivery of therapeutic 
nanoparticles.  These agents would enable a comprehensive understanding of the delivery of 
nanomedicines to tumor lesions as a function of indication and anatomical location.  
Identification of patient characteristics correlating with effective nanoparticle delivery has 
potential to greatly benefit patients and dramatically influence clinical development decisions.  
Prospectively defined clinical trials will be needed to formally establish the relationships 
between therapeutic nanoparticle tumor delivery and treatment outcome.  
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Figures Legends: 
Fig. 1. Biodistribution of 64Cu-MM-302 in patients. Maximum-intensity-projection PET 
images of two patients with HER2-positive breast cancer injected with 30 mg/m2 of MM-
302 and a tracer dose of 64Cu-MM-302 (400 MBq).  PET/CT Images were acquired at 
(A) 0.6 and 19 h post-injection in Patient 02, and (B) 0.7, 24, and 47 h post-injection in 
Patient 06.  Immediately post-administration, 64Cu-MM-302 activity was primarily 
confined in the blood pool because of the extended circulation property of liposomes.  On 
Days 2 and 3, 64Cu-MM-302 uptake was evident in normal spleen and liver, as well as in 
various tumor lesions. 
 
Fig. 2.  Tissue deposition kinetics of 64Cu-MM-302.  Image-based quantification of 64Cu-MM-
302 normal tissue deposition kinetics in HER2-positive breast cancer patients.  A 
spherical ROI was drawn in normal tissues on the PET/CT images to obtain SUVmedian for 
(A) liver, (B) spleen, (C) muscle (quadriceps), (D) lung, (E) bone marrow, and (F) aorta 
(blood).  Deposition of 64Cu-MM-302 is expressed as percentage of injected dose per 
kilogram of tissue (%ID/kg) and is decay corrected.  (G) Circulation half-life of 64Cu-
MM-302 for individual patients was fit with a one-compartment model.  The shaded area 
represents t1/2 (geometric mean, with 95% CI) obtained from Phase 1 MM-302 PK study 
by measuring doxorubicin content in the patient plasma at 30 mg/m2.  Closed and open 
symbols represent patient data in Arm 3 (no cyclophosphamide) and Arm 4 (with 
cyclophosphamide) of the Phase 1 study, respectively. 
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Fig. 3.  Visualization of 64Cu-MM-302 lesion deposition.  Representative PET and fused 
PET/CT images of 64Cu-MM-302 in lesions at different anatomical locations.  Intensity 
scale bars represent deposition from 0 to 10 %ID/kg (derived from SUVmedian).  The 
regions of interest used to measure tumor deposition of 64Cu-MM-302 are shown in blue 
or turquoise outlines.  64Cu-MM-302 uptake was detected at above muscle background 
level in lesions of various anatomical locations that are common for HER2-positive 
metastatic diseases. 
 
Fig. 4.  Quantification of 64Cu-MM-302 uptake in tumor lesions.  (A) Lesion uptake of 64Cu-
MM-302 in patients on Days 2 and 3 in patients treated with (open square) and without 
(closed circle) cyclophosphamide (cyclo).  No significant difference in lesion deposition 
was observed between the two treatment groups (p ≥ 0.67, Mann-Whitney test).  (B) 
64Cu-MM-302 deposition kinetics in all patient lesions illustrating accumulation of MM-
302 in lesions from Day 1 to 3.  Statistical difference in lesion uptake was only detectable 
from Day 1 (p < 0.0001, ANOVA), but not between Days 2 and 3 (p > 0.67).  (C) Tumor 
deposition of 64Cu-MM-302 in individual patients was shown to be highly variable.  No 
correlation of tumor deposition was detected with (D) blood exposure or (E) tumor size.  
(F) 64Cu-MM-302 deposition in lesions of different anatomical locations.  Panels (C-F) 
include data obtained on Day 2, or Day 3 if patient did not undergo PET scan on Day 2. 
 
Fig. 5.  Kinetics of 64Cu-MM-302 deposition in tumor lesions.  Lesion deposition kinetics of 
64Cu-MM-302 in a HER2-positive breast cancer patient who received 3 PET/CT scans at 
0.7 h, 24 h, and 47 h post-injection (Patient 06).  (A) Lesion deposition for each ROI is 
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expressed as %ID/kg derived from SUVmedian (decay-corrected).  (B) Sagittal view of 
PET images illustrating deposition in ROI 3 (chest wall mass) and ROI 4 (left cervical 
lymph node).  (C) Schematic diagram of PK model describing 64Cu-MM-302 transport 
kinetics post-injection.  (D) Blood and lesion deposition data fit to the model described in 
(C), illustrating 64Cu signal contribution kinetics from tumor vascular vs. tumor tissue 
compartments at 0 to 168 h post-injection. 
 
Fig. 6.  Patient treatment outcome stratified by deposition of lowest uptake lesion.  (A) 
64Cu-MM-302 lesion deposition of the lowest uptake lesion within each patient from 
Days 2 or 3 are shown and aligned in ascending order.  A deposition threshold was 
selected based on the inflection point of the deposition graph and confirmed by ROC 
analysis, where patients to the left of the inflection point were designated as “low uptake” 
group.  The inset figures illustrate the percentage of patients with >1 lesion that are below 
or above the cutoff (top inset), and percentage of lesions that are below or above the 
cutoff (bottom inset).  PFS of the imaged patients are shown in (B), where “low uptake” 
patients are depicted with orange striped bars, and “high uptake” patients are depicted 
with black solid bars.  The best overall response per RECIST v1.1 criteria was captured 
in (C) stratified into the “low uptake” and “high uptake” groups, where PR, SD, and PD 
represent partial response, stable disease, and progressive disease, respectively.  (D) 
Patient PFS of the high vs. low uptake patients were shown in a Kaplan-Meier curve. 
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